The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 09, 2019

Filed:

Feb. 08, 2018
Applicant:

Ionis Pharmaceuticals, Inc., Carlsbad, CA (US);

Inventors:

W. Brad Wan, Fallbrook, CA (US);

Michael T. Migawa, Carlsbad, CA (US);

Michael Oestergaard, Carlsbad, CA (US);

Eric E. Swayze, Encinitas, CA (US);

Punit P. Seth, Carlsbad, CA (US);

Assignee:

Ionis Pharmaceuticals, Inc., Carlsbad, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); C07H 19/067 (2006.01); C07H 19/167 (2006.01); C07H 21/02 (2006.01); C07H 19/06 (2006.01); C07H 19/16 (2006.01); C07H 21/00 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
C12N 15/111 (2013.01); C07H 19/06 (2013.01); C07H 19/067 (2013.01); C07H 19/16 (2013.01); C07H 19/167 (2013.01); C07H 21/00 (2013.01); C07H 21/02 (2013.01); C12N 15/1135 (2013.01); C12N 15/1136 (2013.01); C12N 15/1137 (2013.01); C12N 15/1138 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/341 (2013.01); C12N 2310/346 (2013.01); C12N 2310/351 (2013.01);
Abstract

The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Such oligomeric compounds have enhanced stability to exposure to base during synthesis. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.


Find Patent Forward Citations

Loading…